Ferenc G Rick

Summary

Publications

  1. pmc An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer
    Ferenc G Rick
    Endocrine, Polypeptide, and Cancer Institute, Veterans Affairs Medical Center and South Florida Veterans Affairs Foundation for Research and Education, University of Miami, Miller School of Medicine, Miami, Florida, USA
    Onco Targets Ther 6:391-402. 2013
  2. ncbi request reprint Agonists of luteinizing hormone-releasing hormone in prostate cancer
    Ferenc G Rick
    Endocrine, Polypeptide, and Cancer Institute, Veterans Affairs Medical Center, South Florida Veterans Affairs Foundation for Research and Education, 1201 NW 16th St, Research 151, Room 2A103C, Miami, FL 33125, USA 1 305 575 3477 1 305 575 3126
    Expert Opin Pharmacother 14:2237-47. 2013
  3. pmc Shrinkage of experimental benign prostatic hyperplasia and reduction of prostatic cell volume by a gastrin-releasing peptide antagonist
    Ferenc G Rick
    Endocrine, Polypeptide and Cancer Institute, Veterans Affairs Medical Center and South Florida Veterans Affairs Foundation for Research and Education, Miami, FL 33125, USA
    Proc Natl Acad Sci U S A 110:2617-22. 2013
  4. doi request reprint Mechanisms of synergism between antagonists of growth hormone-releasing hormone and antagonists of luteinizing hormone-releasing hormone in shrinking experimental benign prostatic hyperplasia
    Ferenc G Rick
    Veterans Affairs Medical Center and South Florida Veterans Affairs Foundation for Research and Education, Miami, Florida 33125, USA
    Prostate 73:873-83. 2013
  5. pmc GHRH antagonist when combined with cytotoxic agents induces S-phase arrest and additive growth inhibition of human colon cancer
    Ferenc G Rick
    Endocrine, Polypeptide and Cancer Institute, Veterans Affairs Medical Center and South Florida Veterans Affairs Foundation for Research and Education, Miami, FL, USA
    Cell Cycle 11:4203-10. 2012
  6. pmc Potentiation of cytotoxic chemotherapy by growth hormone-releasing hormone agonists
    Miklós Jászberényi
    Veterans Affairs VA Medical Center, Miami, FL 33125
    Proc Natl Acad Sci U S A 111:781-6. 2014
  7. pmc Inhibition of U-87 MG glioblastoma by AN-152 (AEZS-108), a targeted cytotoxic analog of luteinizing hormone-releasing hormone
    Miklós Jászberényi
    Veterans Affairs Medical Center, Miami, FL, USA
    Oncotarget 4:422-32. 2013
  8. pmc Antagonists of growth hormone-releasing hormone inhibit growth of androgen-independent prostate cancer through inactivation of ERK and Akt kinases
    Ferenc G Rick
    Endocrine, Polypeptide and Cancer Institute, Veterans Affairs Medical Center and South Florida Veterans Affairs Foundation for Research and Education, Miami, FL 33125, USA
    Proc Natl Acad Sci U S A 109:1655-60. 2012
  9. pmc Antagonists of growth hormone-releasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasia
    Ferenc G Rick
    Veterans Affairs Medical Center, Miami, FL 33125, USA
    Proc Natl Acad Sci U S A 108:3755-60. 2011
  10. doi request reprint Powerful inhibition of in-vivo growth of experimental hepatic cancers by bombesin/gastrin-releasing peptide antagonist RC-3940-II
    Karoly Szepeshazi
    Veterans Affairs Medical Center Miami, Miami, FL 33125, USA
    Anticancer Drugs 23:906-13. 2012

Collaborators

Detail Information

Publications25

  1. pmc An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer
    Ferenc G Rick
    Endocrine, Polypeptide, and Cancer Institute, Veterans Affairs Medical Center and South Florida Veterans Affairs Foundation for Research and Education, University of Miami, Miller School of Medicine, Miami, Florida, USA
    Onco Targets Ther 6:391-402. 2013
    ..Degarelix thus represents an important addition to the hormonal armamentarium for therapy of advanced androgen-dependent prostate cancer...
  2. ncbi request reprint Agonists of luteinizing hormone-releasing hormone in prostate cancer
    Ferenc G Rick
    Endocrine, Polypeptide, and Cancer Institute, Veterans Affairs Medical Center, South Florida Veterans Affairs Foundation for Research and Education, 1201 NW 16th St, Research 151, Room 2A103C, Miami, FL 33125, USA 1 305 575 3477 1 305 575 3126
    Expert Opin Pharmacother 14:2237-47. 2013
    ..The agonists of luteinizing hormone-releasing hormone (LHRH), also called gonadotropin-releasing hormone, are still the most frequently used form of medical ADT...
  3. pmc Shrinkage of experimental benign prostatic hyperplasia and reduction of prostatic cell volume by a gastrin-releasing peptide antagonist
    Ferenc G Rick
    Endocrine, Polypeptide and Cancer Institute, Veterans Affairs Medical Center and South Florida Veterans Affairs Foundation for Research and Education, Miami, FL 33125, USA
    Proc Natl Acad Sci U S A 110:2617-22. 2013
    ..GRP antagonists should be considered for further development as therapy for BPH...
  4. doi request reprint Mechanisms of synergism between antagonists of growth hormone-releasing hormone and antagonists of luteinizing hormone-releasing hormone in shrinking experimental benign prostatic hyperplasia
    Ferenc G Rick
    Veterans Affairs Medical Center and South Florida Veterans Affairs Foundation for Research and Education, Miami, Florida 33125, USA
    Prostate 73:873-83. 2013
    ..We investigated the mechanisms of action of this combination on cell cycle traverse and expression of prostatic genes...
  5. pmc GHRH antagonist when combined with cytotoxic agents induces S-phase arrest and additive growth inhibition of human colon cancer
    Ferenc G Rick
    Endocrine, Polypeptide and Cancer Institute, Veterans Affairs Medical Center and South Florida Veterans Affairs Foundation for Research and Education, Miami, FL, USA
    Cell Cycle 11:4203-10. 2012
    ..Our observations indicate that JMR-132 enhances the antiproliferative effect of S-phase-specific cytotoxic drugs by causing accumulation of tumor cells in S-phase...
  6. pmc Potentiation of cytotoxic chemotherapy by growth hormone-releasing hormone agonists
    Miklós Jászberényi
    Veterans Affairs VA Medical Center, Miami, FL 33125
    Proc Natl Acad Sci U S A 111:781-6. 2014
    ..These findings indicate that the GHRH agonists can potentiate the anticancer activity of the traditional chemotherapeutic drug, DOX, by multiple mechanisms including the induction of differentiation of cancer cells. ..
  7. pmc Inhibition of U-87 MG glioblastoma by AN-152 (AEZS-108), a targeted cytotoxic analog of luteinizing hormone-releasing hormone
    Miklós Jászberényi
    Veterans Affairs Medical Center, Miami, FL, USA
    Oncotarget 4:422-32. 2013
    ..Our findings suggest that targeted cytotoxic analog AN-152 (AEZS-108) should be considered for a treatment of glioblastomas...
  8. pmc Antagonists of growth hormone-releasing hormone inhibit growth of androgen-independent prostate cancer through inactivation of ERK and Akt kinases
    Ferenc G Rick
    Endocrine, Polypeptide and Cancer Institute, Veterans Affairs Medical Center and South Florida Veterans Affairs Foundation for Research and Education, Miami, FL 33125, USA
    Proc Natl Acad Sci U S A 109:1655-60. 2012
    ..Our findings support the role of GHRH as an autocrine growth factor in prostate cancer and suggest that antagonists of GHRH should be considered for further development as therapy for CRPC...
  9. pmc Antagonists of growth hormone-releasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasia
    Ferenc G Rick
    Veterans Affairs Medical Center, Miami, FL 33125, USA
    Proc Natl Acad Sci U S A 108:3755-60. 2011
    ..This study sheds light on the mechanism of action of GHRH antagonists in BPH and suggests that GHRH antagonists should be considered for further development as therapy for BPH...
  10. doi request reprint Powerful inhibition of in-vivo growth of experimental hepatic cancers by bombesin/gastrin-releasing peptide antagonist RC-3940-II
    Karoly Szepeshazi
    Veterans Affairs Medical Center Miami, Miami, FL 33125, USA
    Anticancer Drugs 23:906-13. 2012
    ..Its effect may be linked to changes in expression of those cancer genes important in angiogenesis, invasion, and metastasis. RC-3940-II may be considered for further investigations in treatment of liver cancers...
  11. doi request reprint LHRH antagonist Cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia
    Ferenc G Rick
    Veterans Affairs Medical Center and South Florida Veterans Affairs Foundation for Research and Education, Miami, Florida 33125, USA
    Prostate 71:736-47. 2011
    ..We investigated the mechanism of action and effect of Cetrorelix in a rat model of BPH...
  12. ncbi request reprint Triple-negative breast cancers express receptors for luteinizing hormone-releasing hormone (LHRH) and respond to LHRH antagonist cetrorelix with growth inhibition
    Stefan Buchholz
    The Endocrine, Polypeptide and Cancer Institute, Veterans Affairs Medical Center and South Florida VA Foundation for Research and Education, Miami, FL 33125, USA
    Int J Oncol 35:789-96. 2009
    ..Given the low toxicity and clinical availability of cetrorelix, this peptide antagonist should be considered for phase II studies in patients with advanced TNBC...
  13. doi request reprint Combining growth hormone-releasing hormone antagonist with luteinizing hormone-releasing hormone antagonist greatly augments benign prostatic hyperplasia shrinkage
    Ferenc G Rick
    Veterans Affairs Medical Center and South Florida Veterans Affairs Foundation for Research and Education, Miami, Florida 33125, USA
    J Urol 187:1498-504. 2012
    ..We investigated the influence of a combination of antagonists of growth hormone-releasing hormone and luteinizing hormone-releasing hormone on animal models of benign prostatic hyperplasia...
  14. pmc Combination of gastrin-releasing peptide antagonist with cytotoxic agents produces synergistic inhibition of growth of human experimental colon cancers
    Ferenc G Rick
    Endocrine, Polypeptide and Cancer Institute, Veterans Affairs Medical Center, Miami, FL, USA
    Cell Cycle 11:2518-25. 2012
    ..single substances (p < 0.05) was significantly greater. These findings support the use of RC-3940-II as an anticancer agent and may help to design clinical trials using RC-3940-II in combinations with cytotoxic agents...
  15. pmc Powerful inhibition of experimental human pancreatic cancers by receptor targeted cytotoxic LH-RH analog AEZS-108
    Karoly Szepeshazi
    Veterans Affairs Medical Center, Miami, FL, USA
    Oncotarget 4:751-60. 2013
    ..Cytotoxic LH-RH analog, AEZS-108, may be a useful agent for the treatment of LH-RH receptor positive advanced pancreatic carcinoma...
  16. ncbi request reprint Inhibition of human non-small cell lung cancers with a targeted cytotoxic somatostatin analog, AN-162
    Andrea Treszl
    Endocrine, Polypeptide and Cancer Institute, Veterans Affairs Medical Center and South Florida Veterans Affairs Foundation for Research and Education, 1201 NW 16th Street, Miami, FL 33125, USA
    Peptides 30:1643-50. 2009
    ..Our results suggest that cytotoxic somatostatin analog AN-162 (AEZS-124) should be considered for the further development of a therapy of patients with NSCLC...
  17. pmc Antagonists of growth hormone-releasing hormone suppress in vivo tumor growth and gene expression in triple negative breast cancers
    Roberto Perez
    Veterans Affairs Medical Center, Miami, FL, USA
    Oncotarget 3:988-97. 2012
    ..Further studies on GHRH antagonists may facilitate the development of new strategies for the treatment of resistant cancers...
  18. pmc Receptor-targeted therapy of human experimental urinary bladder cancers with cytotoxic LH-RH analog AN-152 [AEZS- 108]
    Karoly Szepeshazi
    Veterans Affairs Medical Center, Miami, FL, USA
    Oncotarget 3:686-99. 2012
    ..These results suggest that targeted cytotoxic LH-RH analog, AN-152 (AEZS- 108), should be examined for treatment of patients with LH-RH receptor positive invasive bladder cancers...
  19. doi request reprint Suppression of the proliferation of human U-87 MG glioblastoma cells by new antagonists of growth hormone-releasing hormone in vivo and in vitro
    Miklós Jászberényi
    Veterans Affairs Medical Center, Miami, FL, 33125, USA
    Target Oncol 8:281-90. 2013
    ..Our findings indicate that GHRH antagonists inhibit growth of GBMs by multiple mechanisms and decrease both tumor cell size and number. ..
  20. pmc Preclinical efficacy of growth hormone-releasing hormone antagonists for androgen-dependent and castration-resistant human prostate cancer
    Cale D Fahrenholtz
    Department of Molecular and Cellular Pharmacology, Miller School of Medicine, University of Miami, Miami, FL 33136
    Proc Natl Acad Sci U S A 111:1084-9. 2014
    ..MIA-602 also further inhibited VCaP xenografts when combined with ADT. This study demonstrates the preclinical efficacy of the GHRH antagonist MIA-602 for treatment of both androgen-dependent and CRPC...
  21. pmc Beneficial effects of novel antagonists of GHRH in different models of Alzheimer's disease
    Miklós Jászberényi
    Endocrine, Polypeptide, and Cancer Institute, Miami Veterans Affairs Medical Center and South Florida VA Foundation for Research and Education, Miami, FL 33125, USA
    Aging (Albany NY) 4:755-67. 2012
    ..Our data strongly suggest the merit of further studies with GHRH analogs in models of Alzheimer's disease and in elementary clinical trials...
  22. ncbi request reprint Synthesis of new potent agonistic analogs of growth hormone-releasing hormone (GHRH) and evaluation of their endocrine and cardiac activities
    Renzhi Cai
    Endocrine, Polypeptide and Cancer Institute, Veterans Affairs Medical Center, Miami, FL, United States South Florida VA Foundation for Research and Education, Miami, FL, United States Department of Pathology, University of Miami, Miller School of Medicine, Miami, FL, United States
    Peptides 52:104-12. 2014
    ....
  23. doi request reprint Dose-dependent growth inhibition in vivo of PC-3 prostate cancer with a reduction in tumoral growth factors after therapy with GHRH antagonist MZ-J-7-138
    Elmar Heinrich
    Veterans Affairs Medical Center, Tulane University School of Medicine, New Orleans, Louisiana, USA
    Prostate 68:1763-72. 2008
    ..Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of various cancers and affect tumoral growth factors...
  24. doi request reprint Hormonal manipulation of benign prostatic hyperplasia
    Ferenc G Rick
    Veterans Affairs Medical Center, South Florida Veterans Affairs Foundation for Research and Education, University of Miami, Miller School of Medicine, Miami, Florida, USA
    Curr Opin Urol 23:17-24. 2013
    ..We also discuss potential new 5-ARIs and other hormonal treatments...
  25. pmc Activation of growth hormone releasing hormone (GHRH) receptor stimulates cardiac reverse remodeling after myocardial infarction (MI)
    Rosemeire M Kanashiro-Takeuchi
    Interdisciplinary Stem Cell Institute and Department of Molecular and Cellular Pharmacology, Miller School of Medicine, University of Miami, Miami, FL 33136, USA
    Proc Natl Acad Sci U S A 109:559-63. 2012
    ..Therefore, activation of GHRHR provides a unique therapeutic approach to reverse remodeling after MI...